Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial RTOG 9410
WJ Curran Jr, R Paulus, CJ Langer… - … the National Cancer …, 2011 - academic.oup.com
… In a randomized phase III trial, 610 patients with inoperable stage II or III non–small cell
lung cancer were randomly assigned to two different concurrent regimens (chemotherapy with …
lung cancer were randomly assigned to two different concurrent regimens (chemotherapy with …
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
J Vansteenkiste, R Pirker, B Massuti… - … the National Cancer …, 2002 - academic.oup.com
… -blind, randomized phase III study tested the safety and efficacy of darbepoetin alfa
administered weekly for the treatment of anemia in patients with lung cancer receiving multicycle …
administered weekly for the treatment of anemia in patients with lung cancer receiving multicycle …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
… patients and the only agent for which phase III data exists in a large number of patients
with prior platinum therapy. In the first of two randomized phase III trials, median survival with …
with prior platinum therapy. In the first of two randomized phase III trials, median survival with …
Phase III randomized trial comparing three platinum-based doublets in advanced non–small-cell lung cancer
GV Scagliotti, F De Marinis, M Rinaldi… - Journal of clinical …, 2002 - ascopubs.org
… Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide
versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (…
versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (…
Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial
F Macbeth, S Noble, J Evans, S Ahmed… - Journal of Clinical …, 2016 - ascopubs.org
… -label, randomized trial to evaluate the addition of a primary prophylactic dose of LMWH
for 24 weeks to standard treatment in patients with newly diagnosed lung cancer of any stage …
for 24 weeks to standard treatment in patients with newly diagnosed lung cancer of any stage …
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the …
DR Spigel, PM Townley, DM Waterhouse… - Journal of clinical …, 2011 - ascopubs.org
… The impact of BV on survival would be best assessed in a larger randomized phase III
setting. A randomized, open-label, parallel assignment phase II to III trial in Europe (IFCT […
setting. A randomized, open-label, parallel assignment phase II to III trial in Europe (IFCT […
Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy
N Hanna, FA Shepherd, FV Fossella… - Journal of clinical …, 2004 - ascopubs.org
… Lung cancer is the most common cancer in the world today (12.3% of all new cases), with …
deaths (17.8% of all cancer deaths) worldwide in 2000. Non—small-cell lung cancer (NSCLC) …
deaths (17.8% of all cancer deaths) worldwide in 2000. Non—small-cell lung cancer (NSCLC) …
Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer
DR Spigel, TJ Ervin, RA Ramlau, DB Daniel… - Journal of clinical …, 2013 - ascopubs.org
… We conducted a global, randomized, placebo-controlled, phase II study in patients with …
A randomized phase III study evaluating erlotinib with or without onartuzumab in patients …
A randomized phase III study evaluating erlotinib with or without onartuzumab in patients …
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer
C Butts, N Murray, A Maksymiuk, G Goss… - Journal of Clinical …, 2005 - ascopubs.org
… Lung cancer remains the leading cause of death from cancer for men and women.
Approximately 80% of patients have non–small-cell lung cancer (NSCLC). The majority of NSCLC …
Approximately 80% of patients have non–small-cell lung cancer (NSCLC). The majority of NSCLC …
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–small-cell lung cancer
GV Scagliotti, U Pastorino, JF Vansteenkiste… - Journal of clinical …, 2012 - ascopubs.org
… , lung cancer continues to be the leading cause of cancer deaths in … cancer combined.
Radical surgery remains the cornerstone of treatment for early-stage non–small-cell lung cancer (…
Radical surgery remains the cornerstone of treatment for early-stage non–small-cell lung cancer (…
相关搜索
- small cell lung cancer randomized phase
- lung cancer randomized phase iib trial
- lung cancer randomized phase iii study
- cell lung cancer randomized clinical trial
- randomized phase iii trial
- lung cancer preoperative chemotherapy
- cell lung cancer first line treatment
- lung cancer low molecular weight heparin
- lung cancer meta analysis
- lung cancer oncology group
- bevacizumab in combination randomized phase
- lung cancer gefitinib in combination
- lung cancer cisplatin plus etoposide
- lung cancer randomized trial
- small cell lung cancer randomized study
- non-small cell lung cancer